News • Mammary tumorigenesis
New marker identifies which breast lesions will progress to cancer
New research contributes to identifying which breast lesions will progress to cancer, thus helping avoid overtreatment
Image source: CNIO; photo: Christian Esposito/Madmoviex
20% of breast cancer diagnoses are actually precancerous lesions. As it is not yet possible to know which ones will progress to cancer, the vast majority are treated as if they were already cancerous. “In other words, a very high number of women are being unnecessarily treated,” explains Eva González-Suárez, researcher at the Spanish National Cancer Research Centre (CNIO). “But at the moment there’s no way to avoid it”. Her new study, published in 'Nature Communications', identifies a marker that discriminates precancerous breast lesions that will develop into tumours. The study also reveals that breast cancers originate in certain cells that the authors refer to as ‘infidel’.
The research has focused on the role of the RANK protein, whose involvement in the genesis of breast tumours was also discovered by González-Suárez in 2010 at the Bellvitge Biomedical Research Institute (IDIBELL), where she still heads a clinical research line.
There are two types of cells in breast tissue: luminal cells, which produce milk, and basal cells, which are contractile and allow that milk to be ejected. Several studies suggested that breast tumours originate exclusively in a subpopulation of luminal cells, known as luminal progenitors. The study now being published, with Jaime Redondo-Pedraza as first author, reveals, however, that tumours start in a different type of cells, referred to as infidel cells by the authors, and which derive from basal cells.
The new research shows that the expression of the RANK protein in basal cells causes them to lose their identity and become new cells that are neither clearly basal nor luminal, but rather hybrid, sharing characteristics from both types. These are the infidel cells.
Recommended article
Article • Research, diagnostics, treatments
Focus on breast cancer
Breast cancer (breast carcinoma; often abbreviated as BRCA) is the most common cancer in women in many countries and the cancer with the highest mortality rate. The diagnostic and therapeutic options for breast cancer are correspondingly diverse. Keep reading for latest developments in early detection, staging, treatment and research.
All types of breast tumours would begin in these ‘traitorous’ cells, including luminal tumours, which express hormone receptors (+), as well as triple negative tumours that do not express them (-).
“What we know now is that basal cells in the breast can give rise to all types of tumours,” explains Eva González. “We could say that a defined cell identity protects against the appearance of tumours. However, when cells lose their initial identity and become these hybrid or infidel cells, regardless of their origin, that’s when cancer arises.”
As we haven’t been able to tell for sure so far, all women diagnosed with these [DCIS] lesions are treated as if it were already cancer
Eva González-Suárez
The group has developed a genetic signature that detects these infidel cells at the origin of precancerous lesions, identifying which of these cells will evolve into invasive tumours. After identifying the genetic signature in mice, Eva González-Suarez’s group tested this new marker on a cohort of human precancerous breast lesions and confirmed that it can identify which lesions will indeed develop into cancer.
“A common diagnosis in breast medicine is ductal carcinoma in situ, which is considered a precancerous lesion, and it was previously impossible to know whether it would progress to cancer,” says González-Suárez. “As we haven’t been able to tell for sure so far, all women diagnosed with these lesions are treated as if it were already cancer. In other words, a very high number of women are being over-treated.”
Diagnoses of these precancerous lesions have increased thanks to screening programmes and the improvement of imaging techniques, to the point that, at this current moment in time, 20% of all cancer diagnoses are these precancerous lesions that are not actually cancer. Among them, only 30% will develop into cancer, but the inability to know which ones has led to the vast majority to be treated as cancer.
The genetic signature identified by Eva González’s group could detect which precancerous lesions will evolve into invasive tumours, that is, into cancer. “Now we still need to confirm the signature with an independent cohort, and refine it to be able to use it in clinical practice to identify which lesions will indeed develop into invasive cancer,” González states.
Source: Spanish National Cancer Research Centre
21.04.2026
